Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2009
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy
Y Segawa, K Aogi, K Inoue, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
August 1, 1989
[Two cases of advanced breast cancer with distant metastasis showing long-term survival with multidisciplinary treatment including intra-arterial infusion chemotherapy]
N Yokoyama, M Murakami, H Doihara, et al.
Breast Cancer Research and Treatment
|
June 24, 2011
Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey
K Kawaguchi, H Ishiguro, S Morita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2009
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
N Katsumata, T Watanabe, H Minami, et al.
International Journal of Cancer
|
July 17, 1997
Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential
K Aogi, M Nishiyama, R Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2010
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
K Tamura, C Shimizu, T Hojo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2015
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry
N Niikura, A Tomotaki, H Miyata, et al.
British Journal of Cancer
|
October 22, 2009
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
M Toi, H Iwata, Y Fujiwara, et al.
Breast Cancer Research and Treatment
|
March 25, 2017
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)
H Kawaguchi, N Masuda, T Nakayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
H Sakai, J Tsurutani, Y Ozaki, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2009
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy
Y Segawa, K Aogi, K Inoue, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|
August 1, 1989
[Two cases of advanced breast cancer with distant metastasis showing long-term survival with multidisciplinary treatment including intra-arterial infusion chemotherapy]
N Yokoyama, M Murakami, H Doihara, et al.
Breast Cancer Research and Treatment
|
June 24, 2011
Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey
K Kawaguchi, H Ishiguro, S Morita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2009
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
N Katsumata, T Watanabe, H Minami, et al.
International Journal of Cancer
|
July 17, 1997
Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential
K Aogi, M Nishiyama, R Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2010
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
K Tamura, C Shimizu, T Hojo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2015
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry
N Niikura, A Tomotaki, H Miyata, et al.
British Journal of Cancer
|
October 22, 2009
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
M Toi, H Iwata, Y Fujiwara, et al.
Breast Cancer Research and Treatment
|
March 25, 2017
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)
H Kawaguchi, N Masuda, T Nakayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
H Sakai, J Tsurutani, Y Ozaki, et al.
Page
of 4